Trial · NCT07655375
Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut
Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatme
- Status
- Recruiting
- Sponsor
- Guy Boeckxstaens
- Study type
- Interventional
- Phase
- No phase
- Enrollment
- 60 participants (planned)
- Start
- Aug 18, 2026
- Primary completion
- October 2027
- Conditions
- IBS (Irritable Bowel Syndrome)
Summary
Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success. Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which probably contributes to the abdominal pain.
Interventions
- Sample collection Other
Locations
1 country: Belgium.
| Facility | City | Country |
|---|---|---|
| University Hospitals Leuven | Leuven, Vlaams-Brabant | Belgium |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.